Last $13.75 USD
Change Today +0.44 / 3.31%
Volume 77.1K
SCMP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

sucampo pharmaceuticals-cl a (SCMP) Snapshot

Open
$13.31
Previous Close
$13.31
Day High
$13.77
Day Low
$13.26
52 Week High
12/11/14 - $14.38
52 Week Low
07/31/14 - $5.80
Market Cap
609.8M
Average Volume 10 Days
309.4K
EPS TTM
$0.25
Shares Outstanding
44.3M
EX-Date
--
P/E TM
55.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for SUCAMPO PHARMACEUTICALS-CL A (SCMP)

sucampo pharmaceuticals-cl a (SCMP) Related Businessweek News

No Related Businessweek News Found

sucampo pharmaceuticals-cl a (SCMP) Details

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, discovery, development, and commercialization of proprietary drugs based on prostones and other drug technologies in the Americas, Europe, and Asia. It is developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, as well as for other therapeutic applications. The company, through its collaboration and license agreement with Takeda Pharmaceutical Co., Ltd., offers AMITIZA in the United States for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; and opioid-induced constipation in adults with chronic non-cancer pain. It also provides AMITIZA in Japan through its collaboration and license agreement with Abbott Japan Co., Ltd., for chronic constipation in adults; and in the United Kingdom and Switzerland for the treatment of chronic idiopathic constipation. In addition, the company markets RESCULA in the United States for the treatment of open-angle glaucoma and ocular hypertension. Its pipeline also includes AMITIZA, which is in Phase III trial for pediatric functional constipation. The company’s other pipeline products consist of IV Ion Channel Activator, which is in Phase IIa clinical trial for the treatment of Lumbar spinal stenosis; PO Ion Channel Activator that is in Phase Ia trial for the treatment of Lumbar spinal stenosis; and cobiprostone, which has completed Phase I clinical development for the treatment of oral mucositis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Bethesda, Maryland.

77 Employees
Last Reported Date: 03/12/14
Founded in 1996

sucampo pharmaceuticals-cl a (SCMP) Top Compensated Officers

Co-Founder, Chairman Emeritus and Scientific ...
Total Annual Compensation: $593.5K
Senior Vice President of Sales & Marketing an...
Total Annual Compensation: $242.8K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $338.9K
Principal Accounting Officer
Total Annual Compensation: $273.9K
Compensation as of Fiscal Year 2013.

sucampo pharmaceuticals-cl a (SCMP) Key Developments

Sucampo Pharmaceuticals, Inc. Appoints John H. Johnson to Board of Directors

Sucampo Pharmaceuticals, Inc. announced the appointment of John H. Johnson, founder, Plum Brook Advisors, to its board of directors (Board). Mr. Johnson brings more than 30 years of leadership experience in the pharmaceutical and biotechnology industry to Sucampo. He recently served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

Sucampo Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 10:50 AM

Sucampo Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 10:50 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

Sucampo Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 04:45 PM

Sucampo Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 04:45 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCMP:US $13.75 USD +0.44

SCMP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $6.05 USD +0.33
Momenta Pharmaceuticals Inc $11.42 USD -0.06
Pernix Therapeutics Holdings Inc $9.05 USD +0.28
Progenics Pharmaceuticals Inc $6.99 USD -0.03
Sagent Pharmaceuticals Inc $25.58 USD +0.31
View Industry Companies
 

Industry Analysis

SCMP

Industry Average

Valuation SCMP Industry Range
Price/Earnings 100.0x
Price/Sales 5.9x
Price/Book 8.3x
Price/Cash Flow 108.0x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUCAMPO PHARMACEUTICALS-CL A, please visit www.sucampo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.